nelotanserin
Small moleculeexperimental
Nelotanserin is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00452179)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 2a (5-HT2a) receptorINVERSE AGONIST
HTR2A inverse agonist
Discontinued did not meet trial endpoints.
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C- Mol. weight
- 437.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNelotanserin ↗
- ChEMBLCHEMBL598172 ↗
Also known as
- apd125
- apd125
- apd-125
- apd-125
- nelotanserin
- nelotanserin
- nelotanserin
- nelotanserin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02871427 | Phase 2 | Aug 1, 2016 | Axovant Sciences Inc |
| NCT02708186 | Phase 2 | Mar 1, 2016 | Axovant Sciences Inc |
| NCT02640729 | Phase 2 | Dec 1, 2015 | Axovant Sciences Inc |
| NCT00664664 | Phase 2 | Apr 1, 2008 | Arena Pharmaceuticals, Duke University |
| NCT00452179 | Phase 2 | Feb 1, 2007 | Arena Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Axovant Sciences Inc | For profit | 3 | 3 | 1 | 2015 |
| Arena Pharmaceuticals | For profit | 2 | 2 | 1 | 2007 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1